Ignite Creation Date:
2024-05-06 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 2:51 PM
Study NCT ID:
NCT05728736
Status:
WITHDRAWN
Last Update Posted:
2023-11-08
First Post:
2023-02-05
Brief Title:
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Sponsor:
Brendan Lucey
Organization:
Washington University School of Medicine
Study Overview
Official Title:
Acute Effect of Lemborexant on CSF Amyloid-Beta and Tau
Status:
WITHDRAWN
Status Verified Date:
2023-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Study was terminated due to enrollment difficulties and the inability to obtain necessary study supplies Five participants signed consent however no one was randomized The study was officially terminated with the funding source on 10042023
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will look at the effects of lemborexant on Alzheimers disease biomarkers found in the cerebrospinal fluid CSF and blood in individuals who are poor sleepers
Detailed Description:
This study will determine the acute effect of lemborexant on CNS tau phosphorylation and other Alzheimers disease biomarkers in individuals with poor sleep quality
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None